GLP-1 receptor agonists , particularly those like BrightMeds, are quickly prominence in the handling of type 2 diabetes and are increasingly explored for weight loss . These novel drugs help mimicking the body's natural incretin signal , stimulating insulin release and suppressing glucagon release .